{"id":70799,"date":"2026-05-12T11:37:16","date_gmt":"2026-05-12T11:37:16","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70799"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"glow","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/glow\/","title":{"rendered":"Mezcla GLOW (BPC-157 10 mg + GHK-Cu 50 mg + TB-500 10 mg)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es GLOW?<\/h3>\n<p style=\"margin: 0;\"><strong>GLOW<\/strong> es una mezcla coformulada de tres p\u00e9ptidos que combina <a href=\"https:\/\/medsbase.com\/es\/bpc-157\/\">BPC-157<\/a> 10 mg, <a href=\"https:\/\/medsbase.com\/es\/ghk-cu\/\">GHK-Cu<\/a> 50 mg, y <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500<\/a> 10\u00a0mg in a single lyophilized vial. The combination covers three complementary regenerative mechanisms in one administration: BPC-157&#8217;s local angiogenic and growth-factor signalling, GHK-Cu&#8217;s copper-mediated dermal remodelling, and TB-500&#8217;s systemic G-actin-binding tissue migration. Each vial contains 70\u00a0mg of total peptide for clinical studies use only.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Composici\u00f3n<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">BPC-157 10 mg + GHK-Cu 50 mg + TB-500 10 mg por vial (proporci\u00f3n en masa 1:5:1, coformulado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>P\u00e9ptido total por vial<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">70 mg de masa pept\u00eddica total<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00fameros CAS de los componentes<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">137525-51-0 (BPC-157) \/ 49557-75-7 (GHK-Cu) \/ 77591-33-4 (TB-500 \/ timosina beta-4)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Perfil de mecanismo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Angiog\u00e9nesis mediada por VEGF (BPC-157) + remodelado d\u00e9rmico mediado por cobre (GHK-Cu) + migraci\u00f3n tisular sist\u00e9mica por uni\u00f3n a G-actina (TB-500) \u2014 tres v\u00edas regenerativas complementarias<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvo coformulado liofilizado (tono azul claro por el Cu unido)<sup>2+<\/sup>)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (cada componente verificado por HPLC, COA disponible bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar dentro de ~30 d\u00edas. Proteger de la luz. No congelar-descongelar la soluci\u00f3n reconstituida.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada). Los tres p\u00e9ptidos se reconstituyen simult\u00e1neamente del mismo vial; la soluci\u00f3n reconstituida debe mantener un leve tono azul por el Cu unido<sup>2+<\/sup> del GHK-Cu.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es GLOW?<\/h2>\n<p><strong>GLOW<\/strong> is a pharmaceutical-grade co-formulated three-peptide blend that combines <a href=\"https:\/\/medsbase.com\/es\/bpc-157\/\">BPC-157<\/a> (Body Protection Compound 157), <a href=\"https:\/\/medsbase.com\/es\/ghk-cu\/\">GHK-Cu<\/a> (complejo de cobre(II) glicil-histidil-lisina), y <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500<\/a> (Thymosin Beta-4 fragment) in a single lyophilized vial at a 1:5:1 mass ratio \u2014 10\u00a0mg BPC-157, 50\u00a0mg GHK-Cu, and 10\u00a0mg TB-500 per vial, for a total of 70\u00a0mg peptide mass. The three peptides represent three of the most cited regenerative-compounds in the published literature, each acting on a different molecular axis: BPC-157 on local angiogenesis and growth-factor signalling, GHK-Cu on copper-mediated dermal remodelling and antioxidant signalling, and TB-500 on systemic G-actin-binding and cell migration. The strategic rationale for the GLOW blend is <strong>mecanismos complementarios, no superpuestos<\/strong> across three regenerative axes. Each component peptide has a distinct molecular target and tissue-distribution pattern, so co-administration covers a broader range of studies endpoints than any single component alone. The blend is intended for studies that benefits from simultaneous activation of all three pathways \u2014 a use case distinct from studies designs that require independent dosing of each component peptide. For studies that needs <strong>dosificaci\u00f3n independiente<\/strong> de cada p\u00e9ptido (dosis diferentes, horarios diferentes, formulaciones de veh\u00edculo diferentes), los componentes tambi\u00e9n est\u00e1n disponibles como viales individuales: <a href=\"https:\/\/medsbase.com\/es\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/es\/ghk-cu\/\">GHK-Cu<\/a>, y <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500<\/a>. Un paquete separado de tres viales \u2014 el <a href=\"https:\/\/medsbase.com\/es\/peptide-healing-stack\/\">Combinaci\u00f3n de P\u00e9ptidos para la Curaci\u00f3n<\/a> (BPC-157 + TB-500 + bacteriostatic water shipped together as three separate vials) \u2014 provides another alternative for studies requiring per-component dose-flexibility. The GLOW co-formulation is specifically for studies at the fixed 1:5:1 mass ratio with single-vial reconstitution. GLOW is supplied as a high-purity lyophilized blend for reconstitution with bacteriostatic water. The reconstituted solution retains a faint blue tint from the bound Cu<sup>2+<\/sup> del componente GHK-Cu \u2014 un indicador cualitativo \u00fatil de que la coordinaci\u00f3n del cobre permaneci\u00f3 intacta durante la liofilizaci\u00f3n y la reconstituci\u00f3n. GLOW <strong>no est\u00e1 aprobado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as a combination or as any of its component peptides. <\/p>\n<h2>Mecanismo de acci\u00f3n \u2014 Tres v\u00edas regenerativas complementarias<\/h2>\n<p>Lo que hace que la coformulaci\u00f3n GLOW sea farmacol\u00f3gicamente distintiva es el <strong>perfil de mecanismo triaxial<\/strong> \u2014 each component activates a fundamentally different regenerative pathway, and the three are non-overlapping at the molecular level. Published studies on each component has established the mechanism in detail; the combination simply delivers all three in a single administration:<\/p>\n<ul>\n<li><strong>BPC-157 (10 mg) \u2014 se\u00f1alizaci\u00f3n VEGF\/NO\/receptor de GH para la reparaci\u00f3n tisular local<\/strong> \u2014 The 15-amino-acid pentadecapeptide derived from gastric juice upregulates VEGFR2 (driving new capillary formation at injury sites), enhances endothelial nitric oxide synthase activity (protecting vascular endothelium), and increases growth-hormone receptor expression on fibroblasts and tenocytes (driving collagen synthesis). Most-cited signal: tendon, ligament, gut barrier, and skeletal muscle recovery. Acts more locally than systemic at the injection site.<\/li>\n<li><strong>GHK-Cu (50 mg) \u2014 remodelaci\u00f3n d\u00e9rmica mediada por cobre y se\u00f1alizaci\u00f3n antioxidante<\/strong> \u2014 El trip\u00e9ptido coordinado con Cu<sup>2+<\/sup>-coordinated tripeptide delivers copper as an enzyme cofactor for lysyl oxidase (collagen\/elastin cross-linking) and superoxide dismutase (oxidative-stress buffering) while signalling on dermal fibroblasts and keratinocytes. Most-cited signal: skin remodelling, wound healing, anti-aging in connective-tissue studies, hair follicle support, copper-axis pharmacology. Higher mass loading (50\u00a0mg in the blend) reflects the larger doses typical of copper-peptide studies vs the microgram-range doses of the other two components.<\/li>\n<li><strong>TB-500 (10 mg) \u2014 Secuestro de G-actina y migraci\u00f3n celular sist\u00e9mica<\/strong> \u2014 The 43-amino-acid thymic peptide is the canonical systemic regenerative compound, binding monomeric G-actin and modulating actin dynamics to drive cell migration, particularly at injury sites. Most-cited signal: systemic muscle and cardiac recovery, vascular repair, and broad systemic distribution that complements BPC-157&#8217;s more localised action. Acts as the &#8220;systemic arm&#8221; to BPC-157&#8217;s &#8220;local arm&#8221;.<\/li>\n<\/ul>\n<p>Las tres v\u00edas son <strong>complementarias desde el punto de vista mecanicista<\/strong>, not redundant: BPC-157 acts locally on the injury site, TB-500 distributes systemically and supports cell migration globally, and GHK-Cu provides copper-cofactor delivery and dermal-tissue-specific signalling. Co-administering the three in study models covers angiogenesis (BPC-157), systemic recovery (TB-500), and dermal-tissue remodelling (GHK-Cu) simultaneously \u2014 a broader studies endpoint coverage than any single component alone. All three peptides have well-tolerated profiles in published preclinical studies, and combination protocols are described in some published studies models of multi-axis tissue regeneration. <\/p>\n<h2>Published Evidence<\/h2>\n<p>GLOW co-formulation is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Multi-axis tissue regeneration<\/strong> \u2014 preclinical models combining systemic and local regenerative endpoints; angiogenesis + cell migration + dermal remodelling in single studies designs<\/li>\n<li><strong>Wound healing studies<\/strong> \u2014 modelos de heridas cut\u00e1neas (espesor total, espesor parcial, quemaduras), cin\u00e9tica de contracci\u00f3n de heridas, formaci\u00f3n de tejido de granulaci\u00f3n, caracterizaci\u00f3n del tejido cicatricial; uno de los enfoques multieje m\u00e1s completos<\/li>\n<li><strong>Recuperaci\u00f3n de tendones, ligamentos y tejidos blandos<\/strong> \u2014 rodent Achilles transection models, medial-collateral-ligament rupture studies; published BPC-157 + TB-500 literature is extensive, with the GHK-Cu addition providing copper-cofactor support for collagen cross-linking<\/li>\n<li><strong>Skin remodelling and dermal studies<\/strong> \u2014 collagen and elastin synthesis, dermal-fibroblast proliferation, photo-aging studies; the GHK-Cu component dominates this studies domain<\/li>\n<li><strong>Comparative co-formulation studies<\/strong> \u2014 comparaci\u00f3n directa con los <a href=\"https:\/\/medsbase.com\/es\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500<\/a>, y <a href=\"https:\/\/medsbase.com\/es\/ghk-cu\/\">GHK-Cu<\/a> brazos independientes; an\u00e1lisis de efectos aditivos frente a sin\u00e9rgicos en la combinaci\u00f3n de tres ejes<\/li>\n<li><strong>Vascular and cardiac recovery<\/strong> \u2014 la se\u00f1al combinada angiog\u00e9nica (BPC-157) y migratoria (TB-500) es muy adecuada para modelos de recuperaci\u00f3n vascular e isquemia cardiaca<\/li>\n<li><strong>Anti-aging and longevity studies<\/strong> \u2014 published work on copper-peptide effects in dermal and connective-tissue aging, particularly relevant for the GHK-Cu component; combined with BPC-157 + TB-500 for broader tissue-aging studies designs<\/li>\n<li><strong>Inflammation and oxidative-stress studies<\/strong> \u2014 copper&#8217;s role as cofactor for superoxide dismutase plus the BPC-157 and TB-500 inflammation-modulating effects provide multi-axis anti-inflammatory studies coverage.<\/li>\n<\/ul>\n<p>Para un contexto m\u00e1s amplio, consulte nuestras <a href=\"https:\/\/medsbase.com\/es\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/es\/ghk-cu\/\">GHK-Cu<\/a>, y <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500<\/a> p\u00e1ginas de productos para la farmacolog\u00eda a nivel de componente, el <a href=\"https:\/\/medsbase.com\/es\/peptide-healing-stack\/\">Combinaci\u00f3n de P\u00e9ptidos para la Curaci\u00f3n<\/a> para el paquete alternativo de tres viales separados (BPC-157 + TB-500 + agua bacteriost\u00e1tica), y el p\u00e9ptido de cobre hermano <a href=\"https:\/\/medsbase.com\/es\/ahk-cu\/\">AHK-Cu<\/a> for hair-axis studies. Browse the full <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Configuraciones Disponibles<\/h2>\n<p>MedsBase ofrece la mezcla GLOW en una \u00fanica coformulaci\u00f3n: <strong>10 mg BPC-157 + 50 mg GHK-Cu + 10 mg TB-500 por vial<\/strong> (proporci\u00f3n de masa 1:5:1, 70 mg de p\u00e9ptidos totales). El vial est\u00e1 disponible en formatos de paquete de 10 o 20 viales con gu\u00eda completa de reconstituci\u00f3n:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Composici\u00f3n del Vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg BPC-157 + 50 mg GHK-Cu + 10 mg TB-500<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard tri-axis regenerative-studies blend \u2014 angiogenesis + dermal remodelling + systemic cell migration in single administration<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 o 20 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three components are supplied at \u226599% HPLC purity (each verified individually) and pre-mixed in the same lyophilized vial. Because the three peptides have different dose ranges and different roles in the blend, the 1:5:1 mass ratio is fixed at manufacture. Users requiring different ratios should use the stand-alone <a href=\"https:\/\/medsbase.com\/es\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/es\/ghk-cu\/\">GHK-Cu<\/a>, y <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500<\/a> vials instead. Compared with purchasing the three components separately, the GLOW co-formulation offers a meaningful cost saving and the practical convenience of single-vial reconstitution at the fixed studies ratio. <\/p>\n<h2>C\u00f3mo se Compara \u2014 Mezcla GLOW vs Peptide Healing Stack<\/h2>\n<p>MedsBase carries two multi-peptide studies products that combine the same broader healing-peptide pharmacology in different packaging formats. The choice between them depends on studies design requirements:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">GLOW Blend<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\"><a href=\"https:\/\/medsbase.com\/es\/peptide-healing-stack\/\">Combinaci\u00f3n de P\u00e9ptidos para la Curaci\u00f3n<\/a><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Formato de envasado<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Vial \u00fanico, coformulado<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Tres viales separados enviados juntos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Composici\u00f3n<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">BPC-157 10 mg + GHK-Cu 50 mg + TB-500 10 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">BPC-157 5 mg + TB-500 5 mg + agua bacteriost\u00e1tica<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>N\u00famero de componentes<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Tres p\u00e9ptidos (incluye p\u00e9ptido de cobre)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dos p\u00e9ptidos + diluyente (sin p\u00e9ptido de cobre)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Flexibilidad de dosis<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Proporci\u00f3n de masa fija 1:5:1 por vial<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Independencia de dosis por componente<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Reconstituci\u00f3n<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Un \u00fanico proceso de reconstituci\u00f3n<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Reconstituci\u00f3n por vial<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Caso de uso<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Convenience + fixed-ratio studies; broader 3-axis coverage including dermal remodelling<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dose-flexible studies; classic 2-axis healing focus (BPC + TB only)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Studies designs that require flexible per-component dosing or that don&#8217;t need the copper-peptide arm should use the <a href=\"https:\/\/medsbase.com\/es\/peptide-healing-stack\/\">Combinaci\u00f3n de P\u00e9ptidos para la Curaci\u00f3n<\/a>. Studies designs that benefit from the broader three-axis coverage (including dermal-tissue remodelling) and that are comfortable with the fixed 1:5:1 mass ratio should use the GLOW blend. Both options are pre-curated for the most-cited healing-peptide studies pharmacology \u2014 the difference is packaging format and component breadth. <\/p>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> almacene los viales liofilizados refrigerados a 2\u20138 \u00b0C en su embalaje original para existencias de trabajo a corto plazo. Para almacenamiento a largo plazo sin abrir, congele a \u221220 \u00b0C. La coformulaci\u00f3n GLOW liofilizada es estable bajo refrigeraci\u00f3n hasta 24 meses y a \u221220 \u00b0C hasta 36 meses. Los tres p\u00e9ptidos componentes tienen perfiles de estabilidad bien emparejados en estado liofilizado. Evite ciclos de congelaci\u00f3n-descongelaci\u00f3n en el polvo liofilizado. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inyecte agua bacteriost\u00e1tica por la pared lateral del vial (no directamente sobre el polvo liofilizado). Como el vial contiene 70 mg de masa pept\u00eddica total, una reconstituci\u00f3n de 2.0 mL produce una concentraci\u00f3n de trabajo de p\u00e9ptidos totales de 35 mg\/mL \u2014 equivalente a 5 mg\/mL de BPC-157, 25 mg\/mL de GHK-Cu y 5 mg\/mL de TB-500. Agite suavemente \u2014 no <strong>ajuste<\/strong> sacuda \u2014 y permita 2\u20135 minutos para una disoluci\u00f3n completa. Una soluci\u00f3n correctamente reconstituida debe ser transparente con un <strong>tono azul p\u00e1lido<\/strong> del Cu unido<sup>2+<\/sup> del componente GHK-Cu \u2014 el color es un indicador cualitativo \u00fatil de que la coordinaci\u00f3n del cobre permaneci\u00f3 intacta durante la liofilizaci\u00f3n y la reconstituci\u00f3n. La turbidez, el precipitado o la ausencia del tono azul indican un problema; deseche e intente nuevamente. <strong>Despu\u00e9s de la reconstituci\u00f3n:<\/strong> almacene refrigerado a 2\u20138 \u00b0C y utilice dentro de los 30 d\u00edas para una estabilidad \u00f3ptima de los tres componentes. No congele la soluci\u00f3n reconstituida \u2014 los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan la integridad del p\u00e9ptido y pueden afectar la coordinaci\u00f3n del cobre. Prot\u00e9jalo de la luz directa en todo momento. Deseche cualquier vial que muestre turbidez, precipitado o decoloraci\u00f3n m\u00e1s all\u00e1 del tono azul p\u00e1lido esperado. <\/p>\n<h2 id=\"faqs\">Preguntas frecuentes<\/h2>\n<h3>What is GLOW used for in studies?<\/h3>\n<p>GLOW is used in studies investigating multi-axis tissue regeneration \u2014 specifically protocols that benefit from simultaneous activation of three complementary regenerative pathways (BPC-157 angiogenesis + GHK-Cu dermal remodelling + TB-500 systemic cell migration) in a single administration. Common contexts include wound healing models, tendon and soft-tissue recovery, skin remodelling, vascular repair, anti-aging connective-tissue studies, and comparative co-formulation pharmacology. The pharmaceutical-grade GLOW sold here is <strong>ajuste<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>\u00bfQu\u00e9 contiene un vial de GLOW?<\/h3>\n<p>Cada vial contiene <strong>10 mg de BPC-157, 50 mg de GHK-Cu y 10 mg de TB-500<\/strong>, co-formulated and lyophilized together as a single powder. Total peptide mass per vial: 70\u00a0mg. The 1:5:1 mass ratio reflects the different studies-relevant dose ranges of the three components (BPC-157 and TB-500 are used in microgram-to-low-milligram doses; GHK-Cu is used in low-to-mid-milligram doses). All three peptides reconstitute simultaneously when bacteriostatic water is added. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia GLOW del Peptide Healing Stack?<\/h3>\n<p>Los dos productos combinan p\u00e9ptidos curativos relacionados pero en diferentes formatos de envasado. <strong>GLOW<\/strong> es un solo vial con tres p\u00e9ptidos (BPC-157 + GHK-Cu + TB-500) coformulados juntos en una proporci\u00f3n fija de 1:5:1. El <a href=\"https:\/\/medsbase.com\/es\/peptide-healing-stack\/\">Combinaci\u00f3n de P\u00e9ptidos para la Curaci\u00f3n<\/a> is three separate vials (BPC-157 + TB-500 + bacteriostatic water) shipped in one parcel. GLOW adds the copper-peptide arm and consolidates reconstitution; the Peptide Healing Stack offers per-component dose independence without the copper-peptide component. Choose based on whether your studies needs the dermal-remodelling axis (GLOW) or per-component dose flexibility (Peptide Healing Stack). <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia GLOW de los p\u00e9ptidos componentes individuales?<\/h3>\n<p>Los componentes tambi\u00e9n est\u00e1n disponibles como productos independientes: <a href=\"https:\/\/medsbase.com\/es\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/es\/ghk-cu\/\">GHK-Cu<\/a>, y <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500<\/a>. Los viales independientes permiten el control de la dosis por componente, diferentes horarios por p\u00e9ptido y diferentes formulaciones de veh\u00edculo por p\u00e9ptido. La coformulaci\u00f3n de GLOW fija la proporci\u00f3n de dosis en 1:5:1 en masa pero ofrece conveniencia (una sola reconstituci\u00f3n, una sola inyecci\u00f3n) y un modesto ahorro de costes en comparaci\u00f3n con la compra de los tres componentes por separado. <\/p>\n<h3>What is the typical GLOW dose?<\/h3>\n<p>Dose depends on the studies endpoint. Conservative protocols use 0.04\u00a0mL of a 35\u00a0mg\/mL reconstituted solution (~200\u00a0mcg BPC-157 + 1\u00a0mg GHK-Cu + 200\u00a0mcg TB-500 per administration) several times weekly. Higher-dose protocols scale up proportionally within the fixed 1:5:1 ratio. Users requiring different ratios should use the stand-alone components rather than the blend. <\/p>\n<h3>\u00bfEst\u00e1 GLOW aprobado por la FDA?<\/h3>\n<p>No. GLOW is not approved by the FDA, EMA, MHRA, or any other major regulator as a combination product. None of the three individual components (BPC-157, GHK-Cu, TB-500) have FDA approval for human therapeutic use either. GHK-Cu is incorporated into some cosmetic products under cosmetic-regulation frameworks, but none of the three peptides is approved as a drug. <\/p>\n<h3>\u00bfPor qu\u00e9 la soluci\u00f3n GLOW tiene un tono azulado?<\/h3>\n<p>El tono azulado proviene del Cu unido<sup>2+<\/sup> del componente GHK-Cu \u2014 espec\u00edficamente de las transiciones electr\u00f3nicas d-d del cobre en el entorno de coordinaci\u00f3n cuadrado-planar creado por el trip\u00e9ptido Gly-His-Lys. El color es un indicador cualitativo \u00fatil de la coordinaci\u00f3n intacta del cobre: una soluci\u00f3n GLOW correctamente reconstituida debe mostrar un ligero tono azul visible; una soluci\u00f3n incolora o p\u00e1lida sugerir\u00eda p\u00e9rdida de cobre o degradaci\u00f3n del componente GHK-Cu. Los otros dos p\u00e9ptidos (BPC-157, TB-500) no aportan color. <\/p>\n<h3>\u00bfC\u00f3mo se debe almacenar GLOW?<\/h3>\n<p>Viales liofilizados: refrigerados a 2\u20138 \u00b0C para stock de trabajo a corto plazo, o \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Soluci\u00f3n reconstituida: refrigerada a 2\u20138 \u00b0C, usar dentro de los 30 d\u00edas. No congele la soluci\u00f3n reconstituida \u2014 los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan la integridad del p\u00e9ptido y podr\u00edan afectar desproporcionadamente la coordinaci\u00f3n del cobre o la estabilidad de la estructura del p\u00e9ptido. Proteja de la luz directa en todo momento. <\/p>\n<h3>\u00bfC\u00f3mo reconstituyo GLOW?<\/h3>\n<p>Siga el procedimiento de reconstituci\u00f3n anterior. A\u00f1ada agua bacteriost\u00e1tica por la pared lateral del vial (no sobre el polvo liofilizado), agite suavemente y permita de 2 a 5 minutos para la disoluci\u00f3n completa. No <strong>ajuste<\/strong> Agite el vial. Los tres p\u00e9ptidos se reconstituyen simult\u00e1neamente desde el mismo vial. Una soluci\u00f3n correctamente reconstituida es clara con un ligero tono azulado. Para un vial + 2,0 mL de diluyente, la concentraci\u00f3n de trabajo es 5 mg\/mL de BPC-157, 25 mg\/mL de GHK-Cu y 5 mg\/mL de TB-500. <\/p>\n<h3>\u00bfQu\u00e9 configuraciones tiene MedsBase en stock?<\/h3>\n<p>MedsBase ofrece GLOW en una \u00fanica coformulaci\u00f3n: 10 mg de BPC-157 + 50 mg de GHK-Cu + 10 mg de TB-500 por vial (70 mg de p\u00e9ptido total, relaci\u00f3n de masa 1:5:1, liofilizado). El vial est\u00e1 disponible en tama\u00f1os de paquete de 10 viales o 20 viales. Cada componente se verifica individualmente con una pureza HPLC \u226599% con un certificado de an\u00e1lisis disponible bajo solicitud. <\/p>\n<h3>\u00bfPuedo comprar los componentes de GLOW por separado?<\/h3>\n<p>S\u00ed \u2014 MedsBase tiene los tres p\u00e9ptidos componentes como productos independientes: <a href=\"https:\/\/medsbase.com\/es\/bpc-157\/\">BPC-157<\/a> en viales de 2\/5\/10 mg, <a href=\"https:\/\/medsbase.com\/es\/ghk-cu\/\">GHK-Cu<\/a>, y <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500<\/a> in 2\/5\/10\u00a0mg vials. Separate vials are useful if protocols require dose ratios other than the fixed 1:5:1 GLOW ratio, or if users want different scheduling per peptide. The co-formulated GLOW blend offers convenience and cost savings for studies at the 1:5:1 ratio. <\/p>\n<h3>Does GLOW cause side reported effects?<\/h3>\n<p>All three component peptides have well-tolerated profiles in published preclinical studies at typical doses. The most consistent finding for the combination is the same as for the individual components: local injection-site reactions, occasional flushing at higher doses, and (rarely) modest skin discolouration at the injection site from copper deposition (from the GHK-Cu component). Systemic adverse effects are uncommon in published preclinical literature for any of the three peptides. <\/p>\n<h3>How long does GLOW take to show effects in preclinical studies?<\/h3>\n<p>Effect onset varies by studies endpoint. Local wound-healing and tissue-recovery effects are typically measurable within 7\u201314 days of regular dosing. Skin-remodelling effects (collagen synthesis, dermal-fibroblast activity) accumulate over 4\u20138 weeks. Systemic regenerative effects mediated by TB-500 develop over similar timescales. The combined three-axis profile produces a broader endpoint coverage than any single component, but the kinetics for each axis follow the timeline of the respective component peptide. <\/p>\n<h3>\u00bfPuedo pedir GLOW para env\u00edo internacional?<\/h3>\n<p>S\u00ed. MedsBase env\u00eda GLOW a todo el mundo desde nuestra red de env\u00edo dedicada a p\u00e9ptidos. Los pedidos solo de p\u00e9ptidos califican para nuestro servicio de env\u00edo independiente de p\u00e9ptidos. Todos los pedidos se env\u00edan en embalaje con control de temperatura con seguimiento completo y est\u00e1n cubiertos por nuestro <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Tissue Regeneration, Wound Healing, and Recovery Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Compuesto de Protecci\u00f3n Corporal \u2014 componente local de angiog\u00e9nesis de GLOW, viales independientes<\/li>\n<li><a href=\"\/es\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 Tripeptido de cobre \u2014 componente de remodelaci\u00f3n d\u00e9rmica de GLOW, viales independientes<\/li>\n<li><a href=\"\/es\/tb-500\/\"><strong>TB-500 (Timosina Beta-4)<\/strong><\/a> \u2014 Fragmento de curaci\u00f3n sist\u00e9mica \u2014 componente de migraci\u00f3n celular sist\u00e9mica de GLOW<\/li>\n<li><a href=\"\/es\/peptide-healing-stack\/\"><strong>Combinaci\u00f3n de P\u00e9ptidos para la Curaci\u00f3n<\/strong><\/a> \u2014 Lote alternativo de tres viales (BPC + TB + agua BAC) sin p\u00e9ptido de cobre<\/li>\n<li><a href=\"\/es\/ahk-cu\/\"><strong>AHK-Cu<\/strong><\/a> \u2014 Sister copper peptide to GHK-Cu \u2014 hair follicle compound<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lecturas adicionales<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore the regenerative-peptide studies landscape<\/strong><\/p>\n<p style=\"margin: 0;\">Explora toda la <a href=\"https:\/\/medsbase.com\/es\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, con compuestos regenerativos relacionados incluyendo <a href=\"https:\/\/medsbase.com\/es\/bpc-157\/\">BPC-157<\/a> (angiog\u00e9nesis local), <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500<\/a> (migraci\u00f3n celular sist\u00e9mica), <a href=\"https:\/\/medsbase.com\/es\/ghk-cu\/\">GHK-Cu<\/a> (remodelaci\u00f3n d\u00e9rmica), y el lote <a href=\"https:\/\/medsbase.com\/es\/peptide-healing-stack\/\">Combinaci\u00f3n de P\u00e9ptidos para la Curaci\u00f3n<\/a> alternativo.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Combinaci\u00f3n regenerativa de tres p\u00e9ptidos coformulados<br \/>\n\u2705 BPC-157 (10mg) + GHK-Cu (50mg) + TB-500 (10mg)<br \/>\n\u2705 Angiog\u00e9nesis local + remodelaci\u00f3n d\u00e9rmica + migraci\u00f3n celular sist\u00e9mica<br \/>\n\u2705 Vial \u00fanico, reconstituci\u00f3n \u00fanica<br \/>\n\u2705 70mg de p\u00e9ptidos totales por vial<\/p>\n<p><strong>GLOW<\/strong> es una mezcla coformulada de p\u00e9ptidos.<\/p>","protected":false},"featured_media":70957,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5440,5449,6291,5441,5442],"class_list":["post-70799","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-bpc-157","product_tag-ghk-cu","product_tag-glow","product_tag-peptide","product_tag-tb-500","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/70799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=70799"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/70957"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=70799"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=70799"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=70799"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=70799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}